Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Drengo
    Junior Member
    • Sep 2019
    • 1

    #1

    Re-mapping contigs or predicted genes?

    Hi!
    I'm quite new to bioinformatics and am currently running into a dilemma on how to approach my re-mapping.
    I have successfully assembled my FASTQ-files (reads) and now have my contigs in FASTA files.
    From these FASTA-files, I want to predict its genes (with Prodigal) and find the depth (abundance) of the predicted genes. However, I am unsure if I should re-map my contigs back to my reads first, or if I should gene predict first, and then re-map the predicted genes back to the reads. As I see it, by re-mapping the predicted genes, I risk losing some of the reads not entirely in the gene. However, by re-mapping the contigs, I get a depth for all the reads on the contig, but will then have to correlate that data to the predicted genes somehow. Do you have any suggestions or preferences? And if you do, why would you choose one over the other.

    Thank you very much in advance!
  • GenoMax
    Senior Member
    • Feb 2008
    • 7142

    #2
    Cross-posted on biostars: https://www.biostars.org/p/398986/

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
      by SEQadmin2



      Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

      Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
      ...
      10-14-2026, 09:55 AM
    • SEQadmin2
      New Genomics Technologies Take Aim at Long-Standing Limits
      by SEQadmin2


      Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

      We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
      ...
      09-28-2026, 10:25 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Yesterday, 11:13 AM
    0 responses
    16 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, Yesterday, 10:48 AM
    0 responses
    15 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-15-2026, 10:52 AM
    0 responses
    35 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-14-2026, 05:39 AM
    0 responses
    42 views
    0 reactions
    Last Post SEQadmin2  
    Working...